Apparently, they didn’t learn too much from Vioxx.
Is Merck stubborn or just dumb?
More in Uncategorized
Past Week
-
Elite access vs. public scrutiny: Medication disparities exposed
-
Too many older adults are taking risky sedative medications
-
The Supreme Court must consider science, not pseudo-science, in public health rulings
-
Navigating organizational dysfunction: lessons from Boeing
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
A Pakistani oncologist’s journey: Navigating commute challenges
-
Past 6 Months
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
Off-label prescriptions, side effects, and lawsuits: Navigating ethical and legal dilemmas
-
The abuser’s playbook: the weaponization of mental health
-
Elite access vs. public scrutiny: Medication disparities exposed
-
Real pain deserves real treatment
-
Wendy Williams’s battle with health and the fragility of success
-
Recent Posts
-
A Pakistani oncologist’s journey: Navigating commute challenges
-
Supporting medical resident families [PODCAST]
-
The Change Healthcare hack: a wake-up call for the health care industry
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
Working patients and health care [PODCAST]
-
Preventing amputations and saving lives starts with bringing PAD into the 21st century
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
